Mylan has become the latest poster child for pharmaceutical industry price-gouging
Government says drug is branded, so drug company should have been paying a far higher reimbursement under pricing rules
Mylan agreed to pay $465 million in a settlement over its pricing practices.
EpiPen maker Mylan agreed to pay $465 million in a settlement with federal regulators over its pricing practices
Mylan will pay $465 million to settle allegations that it overbilled Medicaid for its life-saving EpiPen allergy injection. The federal government says EpiPen is a branded drug, which means Mylan should have been paying a far higher...